2021
How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2015
Does “two is better than one” apply to surgeons? Comparing single-surgeon and cosurgeon bilateral mastectomy outcomes.
Nimbkar S, Mallory M, Losk K, Camuso K, Golshan M. Does “two is better than one” apply to surgeons? Comparing single-surgeon and cosurgeon bilateral mastectomy outcomes. Journal Of Clinical Oncology 2015, 33: 35-35. DOI: 10.1200/jco.2015.33.28_suppl.35.Peer-Reviewed Original ResearchOverall surgery timeSingle surgeonBilateral mastectomyTotal breast weightSurgery timeBreast weightCS casesTissue expander reconstructionStage of cancerAlternative operative approachAxillary dissectionAxillary procedurePostoperative complicationsComplication rateMedical chartsPatient ageOperative recordsUnilateral mastectomyExpander reconstructionBreast surgeonsSurgical timeOperative approachPatient outcomesBivariate analysisLarger study